These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24369334)

  • 1. Long-lasting unspecific intestinal inflammation in ankylosing spondylitis evolving into Crohn's disease.
    Tursi A; Inchingolo CD
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):472-3. PubMed ID: 24369334
    [No Abstract]   [Full Text] [Related]  

  • 2. New insights on fibrosis in Crohn's disease.
    Bailey JR; Whiting CV; Tarlton JF; Bland PW; Probert CS
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):497-9. PubMed ID: 23984996
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history and long-term clinical course of Crohn's disease.
    Freeman HJ
    World J Gastroenterol; 2014 Jan; 20(1):31-6. PubMed ID: 24415855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections.
    Temel T; Cansu DÜ; Korkmaz C; Kaşifoğlu T; Özakyol A
    Int J Rheum Dis; 2015 Jan; 18(1):40-5. PubMed ID: 25195983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept-induced Crohn's disease in ankylosing spondylitis: a case report and review of the literature.
    Tolu S; Rezvani A; Hindioglu N; Calkin Korkmaz M
    Rheumatol Int; 2018 Nov; 38(11):2157-2162. PubMed ID: 30293157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
    Rebelo A; Leite S; Cotter J
    BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Omalizumab with Another Biotherapy.
    Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
    Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases.
    Billmeier U; Dieterich W; Neurath MF; Atreya R
    World J Gastroenterol; 2016 Nov; 22(42):9300-9313. PubMed ID: 27895418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
    Bates J; Diehl L
    J Pathol; 2014 Jan; 232(2):112-20. PubMed ID: 24122796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ankylosing spondylitis or Crohn's disease? Case report and review of the literature.
    Zahiu DC; Rimbaş M; Nicolau A; Zurac S; Voiosu MR
    Rom J Intern Med; 2010; 48(4):347-53. PubMed ID: 21528764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocyte migration test in Crohn's disease, ulcerative colitis, and ankylosing spondylitis using Crohn's colon homogenate, mitochondrial, and microsomal fractions.
    Williams MJ; Richens ER; Gough KR; Ancill RJ
    Am J Dig Dis; 1975 May; 20(5):425-9. PubMed ID: 1130367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery for Crohn's disease and anti-TNF agents: the changing scenario.
    Sorrentino D; Fogel S; Van den Bogaerde J
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):689-700. PubMed ID: 24161133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate for inflammatory bowel disease: time for reconsideration.
    Nielsen OH; Ainsworth MA; Steenholdt C
    Expert Rev Gastroenterol Hepatol; 2019 May; 13(5):407-409. PubMed ID: 30895827
    [No Abstract]   [Full Text] [Related]  

  • 15. HL-A (transplantation) antigens in ankylosing spondylitis and Crohn's disease.
    Russell AS; Schlaut J; Percy JS; Dossetor JB
    J Rheumatol; 1974 Jun; 1(2):203-9. PubMed ID: 4457643
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of genetics in Crohn's disease: how could it influence future therapies?
    Geremia A; Satsangi J
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1075-1077. PubMed ID: 30124365
    [No Abstract]   [Full Text] [Related]  

  • 17. Systemic and mucosal antibodies to Klebsiella in patients with ankylosing spondylitis and Crohn's disease.
    O'Mahony S; Anderson N; Nuki G; Ferguson A
    Ann Rheum Dis; 1992 Dec; 51(12):1296-300. PubMed ID: 1485810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies.
    Winter RW; Burakoff R
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):95-97. PubMed ID: 27900879
    [No Abstract]   [Full Text] [Related]  

  • 19. Impaired peripheral Th1 CD4+ T cell response to Escherichia coli proteins in patients with Crohn's disease and ankylosing spondylitis.
    Ergin A; Syrbe U; Scheer R; Thiel A; Adam T; Büssow K; Duchmann R; Zeitz M; Sieper J
    J Clin Immunol; 2011 Dec; 31(6):998-1009. PubMed ID: 21901394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.